Symptomatic reflux disease: The present, the past and the future

Gut

Volumn 63, Issue 7, 2014, Pages 1185-1193

  Boeckxstaens, Guy ^a   El Serag, Hashem B ^b   Smout, André J P M ^c   Kahrilas, Peter J ^d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROTON PUMP INHIBITOR;

ABDOMINAL OBESITY; AGE; ARTICLE; DISEASE COURSE; DRUG EFFICACY; ESOPHAGEAL ADENOCARCINOMA; ETHNICITY; GASTROESOPHAGEAL REFLUX; HEREDITY; HIATUS HERNIA; HUMAN; INCIDENCE; LAPAROSCOPIC SURGERY; LIFESTYLE MODIFICATION; NEUROMUSCULAR DISEASE; PATHOGENESIS; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; STOMACH FUNDOPLICATION; STOMACH PH; TREND STUDY; WEIGHT REDUCTION;

ANTACIDS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; GASTROESOPHAGEAL REFLUX; HUMANS; LAPAROSCOPY; LIFE STYLE; PROTON PUMP INHIBITORS; RISK FACTORS; RISK REDUCTION BEHAVIOR; WORLD HEALTH;

EID: 84902279411     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-306393     Document Type: Article

References (97)

1. Numans ME, Lau J, de Wit NJ, et al. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004;140:518-27.
2. Kahrilas PJ, Shaheen NJ, Vaezi M; AGAI Medical Position Panel on GERD management. AGAI medical position statement: management of gastroesophageal reflux disease. Gastroenterology 2008;135:1383-91.
3. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastro-oesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20.
4. Kahrilas PJ, Jonsson A, Denison H, et al. Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy. Gut 2014;63:720-6.
5. Kahrilas PJ, Boeckxstaens G, Smout AJPM. Management of the patient with incomplete response to PPI therapy. Best Pract Res Clin Gastroenterol 2013;27:401-14.
6. El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014;63:871-80.
7. El-Serag HB, Mason AC, Petersen N, et al. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 2002;50:368-72. (Pubitemid 34161053)
8. Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol 2012;23:3155-62.
9. Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer 2009;101:855-9.
10. Kramer JR, Fischbach LA, Richardson P, et al. Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men. Clin Gastroenterol Hepatol 2013;11:373-81.e1.
11. Singh S, Sharma AN, Murad MH, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013;11:1399-412.e7.
12. Lagergren J, Mattsson F, Nyrén O. Gastroesophageal reflux does not alter effects of body mass index on risk of esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2014;12:45-51.
13. El-Serag H. Role of obesity in GORD-related disorders. Gut 2008;57:281-4. (Pubitemid 351288088)
14. El-Serag HB, Hashmi A, Garcia J, et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut 2014;63:220-9.
15. Duggan C, Onstad L, Hardikar S, et al. Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2013;11:934-43.
16. Liska D, Dufour S, Zern TL, et al. Interethnic differences in muscle, liver, and abdominal fat partitioning in obese adolescents. PLoS ONE 2007;2:e569.
17. Erichsen R, Robertson D, Farkas DK, et al. Erosive reflux disease increases risk for esophageal adenocarcinoma, compared with nonerosive reflux. Clin Gastroenterol Hepatol 2012;10:475-80.e1.
18. Nelson SP, Kothari S, Wu EQ, et al. Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy. J Med Econ 2009;12:348-55.
19. El-Serag HB, Gilger M, Carter J, et al. Childhood GERD is a risk factor for GERD in adolescents and young adults. Am J Gastroenterol 2004;99:806-12. (Pubitemid 39090204)
20. El-Serag HB, Richardson P, Pilgrim P, et al. Determinants of gastroesophageal reflux disease in adults with a history of childhood gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2007;5:696-701. (Pubitemid 46830058)
21. Thrift AP, Kramer JR, Qureshi Z, et al. Age at onset of GERD symptoms predicts risk of Barrett's esophagus. Am J Gastroenterol 2013;108:915-22.
22. Singh S, Garg SK, Singh PP, et al. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut Published Online First: 12 Nov 2013. doi:10.1136/gutjnl-2013-305997
23. Fischbach LA, Nordenstedt H, Kramer JR, et al. The association between Barrett's esophagus and Helicobacter pylori infection: a meta-analysis. Helicobacter 2012;17:163-75.
24. Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila) 2008;1:329-38.
25. Rubenstein JH, Inadomi JM, Scheiman J, et al. Association between Helicobacter pylori and Barrett's esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol 2014;12:239-45.
26. El-Serag HB, Sonnenberg A, Jamal MM, et al. Corpus gastritis is protective against reflux oesophagitis. Gut 1999;45:181-5. (Pubitemid 29333765)
27. Fischbach L, Graham DY, Kramer JR, et al. Association between Helicobacter pylori and Barrett's esophagus: a case-control study. Am J Gastroenterol Published Online First: 14 Jan 2014. doi:10.1038/ajg.2013.443
28. West T. A treatise on pyrosis idiopathica, or water-brash, as contrasted with certain forms of indigestion and of organic lesions of the abdominal organs; together with the remedies dietetic and medicinal. Longman, Orme, Brown, Green, and Longmans. London, 1841.
29. Winkelstein A. peptic esophagitis. JAMA 1935;104:906-9.
30. Stylopoulos N, Rattner SW. The history of hiatal hernia surgery from Bowditch to laparoscopy. Ann Surg 2005;241:185-93. (Pubitemid 40041008)
31. Cohen S, Harris LD. Does hiatus hernia affect competence of the gastroesophageal sphincter? N Engl J Med 1971;284:1053-6.
32. Mittal RK, Rochester DF, McCallum RW. Electrical and mechanical activity in the human lower esophageal sphincter during diaphragmatic contraction. J Clin Invest 1988;81:1182-9.
33. Sloan S, Rademaker AW, Kahrilas PJ. Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both? Ann Intern Med 1992;117:977-82.
34. Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 1980;65:256-67. (Pubitemid 10159855)
35. Mittal RK, Holloway RH, Penagini R, et al. Transient lower esophageal sphincter relaxation. Gastroenterology 1995;109:601-10.
36. Mittal RK, Lange RC, McCallum RW. Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia. Gastroenterology 1987;92:130-5. (Pubitemid 17207671)
37. Sloan S, Kahrilas PJ. Impairment of esophageal emptying with hiatal hernia. Gastroenterology 1991;100:596-605.
38. Jones MP, Sloan SS, Jovanovic B, et al. Impaired egress rather than increased access: an important independent predictor of erosive esophagitis. Neurogastroenterol Mot 2002;14:625-31. (Pubitemid 35472014)
39. Pandolfino JE, Shi G, Curry J, et al. Esophagogastric junction distensibility: a factor contributing to sphincter incompetence. Am J Physiol Gastrointest Liver Physiol 2002;282:G1052-8. (Pubitemid 34651612)
40. Pandolfino JE, Shi G, Trueworthy B, et al. Esophagogastric junction opening during relaxation distinguishes nonhernia reflux patients, hernia patients, and normal subjects. Gastroenterology 2003;125:1018-24. (Pubitemid 37193448)
41. Woodland P, Sifrim D. The refluxate: the impact of its magnitude, composition and distribution. Best Pract Res Clin Gastroenterol 2010;24:861-71.
42. Rohof WO, Bennink RJ, de Jonge H, et al. Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol Published Online First: 1 Nov. 2013. doi:10.1016/j.cgh.2013.10.026
43. Cannon WB. The movements of the stomach, studied by means of the röntgen rays. J Boston Soc Med Sci 1898;2:59-66.
44. Fletcher J, Wirz A, Henry E, et al. Studies of acid exposure immediately above the gastroesophageal squamocolumnar junction: evidence of short segment reflux. Gut 2004;53:168-73. (Pubitemid 38125501)
45. Fletcher J, Wirz A, Young J, et al. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001;121:775-83. (Pubitemid 32959387)
46. Beaumont H, Bennink RJ, de Jong J, et al. The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GERD. Gut 2010;59:441-51.
47. Kahrilas PJ, McColl K, Fox M, et al. The acid pocket: a target for treatment in reflux disease. Am J Gastroenterol 2013;108:1058-64.
48. Pandolfino JE, Zhang QG, Ghosh SK, et al. Transient lower esophageal sphincter relaxations and reflux: mechanistic analysis using concurrent fluoroscopy and high-resolution manometry. Gastroenterology 2006;131:1725-33. (Pubitemid 44958510)
49. Mittal RK. Longitudinal muscle of the esophagus: its role in esophageal health and disease. Curr Opin Gastroenterol 2013;29:421-30.
50. Kahrilas PJ, Lin S, Chen J, et al. The effect of hiatus hernia on gastro-esophageal junction pressure. Gut 1999;44:476-82. (Pubitemid 29169946)
51. Kahrilas PJ, Shi G, Manka M, et al. Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. Gastroenterology 2000;118:688-95. (Pubitemid 30171618)
52. van Herwaarden MA, Samsom M, Smout AJ. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology 2000;119:1439-46. (Pubitemid 32198668)
53. Pandolfino JE, Zhang Q, Ghosh SK, et al. Acidity surrounding the squamocolumnar junction in GERD patients: "acid pocket" versus "acid film". Am J Gastroenterol 2007;102:2633-41. (Pubitemid 350179327)
54. Bredenoord AJ, Weusten BL, Timmer R, et al. Intermittent spatial separation of diaphragm and lower esophageal sphincter favors acidic and weakly acidic reflux. Gastroenterology 2006;130:334-40. (Pubitemid 43202033)
55. Robertson EV, Derakhshan MH, Wirz AA, et al. Central obesity in asymptomatic volunteers is associated with increased intrasphincteric acid reflux and lengthening of the cardiac mucosa. Gastroenterology 2013;145:730-9.
56. Lee YY, Wirz AA, Whiting JG, et al. Waist belt and central obesity cause partial hiatus hernia and short-segment acid reflux in asymptomatic volunteers. Gut 2014;63:1053-60.
57. Pandolfino JE, El-Serag HB, Zhang Q, et al. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology 2006;130:639-49. (Pubitemid 43374513)
58. Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. Gut 2008;57:674-83. (Pubitemid 351579984)
59. Kahrilas PJ, Smith JA, Dicpinigaitis PV. A causal relationship between cough and gastroesophageal reflux disease (GERD) has been established: a pro/con debate. Lung 2014;192:39-46.
60. Kahrilas PJ, Boeckxstaens G. Failure of reflux inhibitors in clinical trials: bad drugs or wrong patients? Gut 2012;61:1501-9.
61. Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011;106:1419-25.
62. Kahrilas PJ, Jonsson A, Denison H, et al. Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012;10:612-19.
63. Kahrilas PJ, Hughes N, Howden CW. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut 2011;60:1473-8.
64. Kahrilas PJ, Howden CW, Hughes N, et al. Response of chronic cough to acid-suppressive therapy in patients with gastroesophageal reflux disease. Chest 2013;143:605-12.
65. Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope 2006;116:254-60. (Pubitemid 44383934)
66. The American Lung Association Asthma Clinical Research Center. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med 2009;360:1487-99.
67. Bredenoord AJ, Weusten BL, Curvers WL, et al. Determinants of perception of heartburn and regurgitation. Gut 2006;55:313-18. (Pubitemid 43268266)
68. Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006;354:2340-8. (Pubitemid 43801279)
69. Singh M, Lee J, Gupta N, et al. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial. Obesity (Silver Spring) 2013;21:284-90.
70. de Jong JR, Besselink MG, van Ramshorst B, et al. Effects of adjustable gastric banding on gastroesophageal reflux and esophageal motility: a systematic review. Obes Rev 2010;11:297-305.
71. Miguel GP, Azevedo JL, de Souza PH, et al. Erosive esophagitis after bariatric surgery: banded vertical gastrectomy versus banded Roux-en-Y gastric bypass. Obes Surg 2011;21:167-72.
72. Braghetto I, Korn O, Csendes A, et al. Laparoscopic treatment of obese patients with gastroesophageal reflux disease and Barrett's esophagus: a prospective study. Obes Surg 2012;22:764-72.
73. Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991;101:1149-58.
74. Bardhan KD, Muller-Lissner S, Bigard MA, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. BMJ 1999;318:502-7. (Pubitemid 29188994)
75. Miner P Jr, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616-20. (Pubitemid 38020098)
76. Fackler WK, Ours TM, Vaezi MF, et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002;122:625-32. (Pubitemid 34173813)
77. Sifrim D, Holloway R, Silny J, et al. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology 2001;120:1588-98. (Pubitemid 32523478)
78. Hemmink GJ, Bredenoord AJ, Weusten BL, et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor? Am J Gastroenterol 2008;103:2446-53.
79. Chander B, Hanley-Williams N, Deng Y, et al. 24 Versus 48-hour Bravo pH monitoring. J Clin Gastroenterol 2012;46:197-200.
80. Leite LP, Johnston BT, Just RJ, et al. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996;91:1527-31. (Pubitemid 26269164)
81. Van Soest EM, Siersema PD, Dieleman JP, et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006;24:377-85. (Pubitemid 43972906)
82. Lidums I, Lehmann A, Checklin H, et al. Control of transient lower esophageal sphincter relaxations and reflux by the GABA (B) agonist baclofen in normal subjects. Gastroenterology 2000;118:7-13. (Pubitemid 30020367)
83. Krarup AL, Ny L, Gunnarsson J, et al. Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain. Scand J Gastroenterol 2013;48:274-84.
84. Broekaert D, Fischler B, Sifrim D, et al. Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2006;23:365-70. (Pubitemid 43382016)
85. Viazis N, Karamanolis G, Vienna E, et al. Selective-serotonin reuptake inhibitors for the treatment of hypersensitive esophagus. Therap Adv Gastroenterol 2011;4:295-300.
86. Kwiatek MA, Roman S, Fareeduddin A, et al. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial 'acid pocket' in symptomatic GERD patients. Aliment Pharmacol Ther 2011;34:59-66.
87. Rohof WO, Bennink RJ, Smout AJ, et al. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2013;11:1585-91.
88. Chen J, de Ruigh A, Pandolfino JE, et al. Gaviscon double action (antacid + alginate) is more effective than antacid alone in controlling post-prandial acid reflux in GERD patients; a double-blind crossover study. UEGW, 2013. http://www.e-learning.ueg.eu/documents-view.html?no-cache=1&eprs%5Br%5D= 20876
89. Sweis R, Kaufman E, Anggiansah A, et al. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients. Aliment Pharmacol Ther 2013;37:1093-102.
90. Thomas E, Wade A, Crawford G, et al. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action)-a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease. Aliment Pharmacol Ther Published Online First: 28 Jan 2014. doi:10.1111/apt.12640
91. Bredenoord AJ, Draaisma WA, Weusten BL, et al. Mechanisms of acid, weakly acidic and gas reflux after anti-reflux surgery. Gut 2008;57:161-6. (Pubitemid 351158040)
92. Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011;305:1969-77.
93. Schwartz MP, Wellink H, Gooszen HG, et al. Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial. Gut 2007;56:20-8. (Pubitemid 46044884)
94. Arts J, Bisschops R, Blondeau K, et al. A double-blind sham-controlled study of the effect of radiofrequency energy on symptoms and distensibility of the gastroesophageal junction in GERD. Am J Gastroenterol 2012;107:222-30.
95. Cadière GB, Van Sante N, Graves JE, et al. Two-year results of a feasibility study on antireflux transoral incisionless fundoplication using EsophyX. Surg Endosc 2009;23:957-64.
96. Ganz RA, Peters JH, Horgan S, et al. Esophageal sphincter device for gastroesophageal reflux disease. N Engl J Med 2013;368:719-27.
97. Rodríguez L, Rodriguez P, Gómez B, et al. Long-term results of electrical stimulation of the lower esophageal sphincter for the treatment of gastroesophageal reflux disease. Endoscopy 2013;45:595-604.